SCHEMBL23901684

SCHEMBL23901684

Cc1cc(C2CCOCC2)nc2c(C(=O)NCCc3ccc(-c4ccco4)cn3)ncn12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 6/20 0.38
CNR2 P34972 2/20 0.38
MAPK1 P28482 3/20 0.37
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
TSHR P16473 1/20 0.34
HKDC1 Q2TB90 1/20 0.34
HSD17B10 Q99714 1/20 0.34
TP53 P04637 1/20 0.33
PRKDC P78527 1/20 0.33
ADA P00813 1/20 0.33
NPC1 O15118 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MAPT P10636 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
PIK3CD O00329 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
PIK3CG P48736 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22472769 0.86 ALDH1A1 (0.38) ALDH1A1LMNATSHRHSD17B10TP53
SCHEMBL23901594 0.82 ALDH1A1 (0.42) MAPK1ALDH1A1HSD17B10TP53MAPT
SCHEMBL22472758 0.81 MAPT (0.37) ALDH1A1LMNATP53ADANPC1
SCHEMBL22472754 0.77 KDM4E (0.39) ALDH1A1HSD17B10ADANPC1TDP1
SCHEMBL22472802 0.76 NPC1 (0.38) MAPK1ALDH1A1HSD17B10ADANPC1
SCHEMBL22472805 0.75 MAPT (0.42) LMNATP53ADAMAPTNPSR1
SCHEMBL23901674 0.75 LMNA (0.38) CNR2MAPK1ALDH1A1LMNATSHR
SCHEMBL22472783 0.75 ALDH1A1 (0.44) MAPK1ALDH1A1LMNAHSD17B10TP53
SCHEMBL23901677 0.74 L3MBTL1 (0.45) MAPK1ALDH1A1LMNATSHRHKDC1
SCHEMBL22472786 0.73 ALDH1A1 (0.39) ALDH1A1HSD17B10ADANPC1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210309661-A1 IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL - R&D INVESTMENTS, S.A. (PT) 2021-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210309661-A1 IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GAA, GBA2 CNR1 218/4885CNR2 220/4885MAPK1 4176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.